THR 18

Drug Profile

THR 18

Alternative Names: Plasminogen activator inhibitor-1-derived 18-mer peptide; THR-18

Latest Information Update: 04 Dec 2015

Price : $50

At a glance

  • Originator Hadassah Medical Organization
  • Developer D-Pharm; Thrombotech
  • Class Antithrombotics; Neuroprotectants; Peptides
  • Mechanism of Action Plasminogen activator inhibitor-1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Stroke
  • Phase I Myocardial infarction; Pulmonary embolism

Most Recent Events

  • 16 Nov 2015 Phase-II clinical trials in Stroke (Combination therapy) in Moldova (IV) (NCT02572336 )
  • 03 Oct 2015 D-Pharm plans a phase II trial for Stroke (Combination therapy) in Moldova (IV) (NCT02572336)
  • 18 Dec 2014 Efficacy and adverse event data from a phase IIa trial in Stroke released by D-Pharm
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top